Patient-Derived Acute Myeloid Leukemia (AML) Models

Summary of AML Model Specifications

J000106132*, Positive for FLT3, NPM1, DNMT3A and IDH1

^{*Passaged Model}

Percent Engraftment of AML J000106132 PDX J000106132 averages 20% engraftment at 8 weeks and 70% at 12 weeks post engraftment in peripheral blood of NSG™-SGM3 mice.

J000106134*, Positive for FLT3 and NPM1

^{*Passaged Model}

Percent Engraftment of AML J000106134 PDX J000106134 averages 45% engraftment at 8 weeks post engraftment in peripheral blood of NSG™-SGM3 mice.

J000106566*, Positive for TP53

^{*Passaged Model}

Percent Engraftment of AML J000106566 PDX J000106566 averages 10% engraftment at 6 weeks and 35% at 8 weeks post engraftment in peripheral blood of NSG™-SGM3 mice.

              ARA-C RESPONSE IN AML MODEL J000106566

J000106566 AML NSG™-SGM3 mice. Growth rate of AML samples detected in
peripheral blood in the presence or absence of Ara-C.  Mice were engrafted with
human AML cells (hCD33+) and treated +/- Ara-C (30mg/kg) for five consecutive days.

J000106124*, No Mutations Identified

^{*Passaged Model}

Percent Engraftment of AML J000106124 PDX J000106124 averages 80% engraftment at 8 weeks post engraftment in peripheral blood of NSG™-SGM3 mice.

J000106143*, Positive for FLT3 ITD, FLT3 TKD, and NPM1

^{*Passaged Model}

Percent Engraftment of AML J000106143 PDX J000106143 averages 50% engraftment at 12 weeks post engraftment in peripheral blood of NSG™-SGM3 mice.

J000106565*, Positive for FLT3 ITD, FLT3 TKD, and NPM1

^{*Passaged Model}

Percent Engraftment of AML J000106565 PDX J000106565 averages 15% engraftment at 8 weeks post engraftment in peripheral blood of NSG™-SGM3 mice.

J000106569*, Positive for FLT3-ITD and NPM1

^{*Passaged Model}

Percent Engraftment of AML J000106569 PDX J000106569 averages 10% engraftment at 8 weeks and 57% at 12 weeks post engraftment in peripheral blood of NSG™-SGM3 mice.

Frequently Asked Questions

In which mouse models were engraftment levels tested?

The currently available models are confirmed to engraft in the NSG™-SGM3 mice.

What engraftment levels do you typically see?

Greater than 5% AML in the peripheral blood of NSG™-SGM3 mice 10-16 weeks post engraftment.

How many AML engrafted mice can be included per order or on study with JAX?

A minimum of 15 mice is required. Approximately 100-500 mice in total can be engrafted depending on the model of interest.

What are passaged AML models?

Some AML tumor models in our portfolio were passaged in vivo. This approach allows JAX to continuously supply the models and retain inventory for use in further studies at later dates if needed.

How long does it take to confirm AML engraftment?

The average time to confirm AML engraftment in the peripheral blood of NSG™-SGM3 mice is 8 weeks post injection. 

References

Elizabeth C. Townsend, et al. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in
         Mice, Cancer Cell, Volume 29, Issue 4, 2016, Pages 574-586, ISSN 1535-6108

Wunderlich et al. 2010. Leukemia. 24(10):1785-8. [PMID: 20686503]